Monday, May 20, 2013 Last update: 1:36 AM
Company Tech News as it Breaks
Trade Events
Dendreon Corporation
News articles for Dendreon Corporation:
Thursday, May 9, 2013
- Dendreon Announces First Quarter 2013 ResultsMay 9, 2013--Dendreon Corporation (Nasdaq:DNDN) today reported results for the first quarter ended March 31, 2013. Net product revenue for the quarter was $67.6 million compared to $82.0 ... read more
Monday, May 6, 2013
- PROVENGE® (sipuleucel-T) Data Presented at An Annual Scientific Urology MeetingMay 6, 2013--Dendreon Corporation (NASDAQ: DNDN) today announced the presentation of three PROVENGE® (sipuleucel-T) abstracts from new and ongoing clinical trials at the ... read more
Wednesday, April 24, 2013
- Dendreon to Host Conference Call on May 9 to Announce First Quarter Financial ResultsApril 24, 2013--Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Thursday, May 9, 2013, at 9:00 a.m. EDT to review first quarter ... read more
Monday, March 18, 2013
- Dendreon Announces Securities Class Action SettlementDendreon Corporation (Nasdaq:DNDN) today announced that it has reached an agreement in principle to settle the securities class action litigation pending against it in the United States District ... read more
Tuesday, March 12, 2013
- Dendreon Announces Webcast Presentation at ROTH ConferenceMarch 12, 2013—Dendreon Corporation (NASDAQ:DNDN) today announced that management will present at the 25th Annual ROTH Conference in Laguna Niguel, California, on March 18, 2013, at 11:00 a.m. ... read more
Monday, February 25, 2013
- Dendreon Announces Fourth Quarter and 2012 Year End ResultsDendreon Corporation (Nasdaq: DNDN) today reported results for the fourth quarter and full year ended December 31, 2012. Net product revenue for the year ended December 31, 2012 ... read more
Wednesday, February 13, 2013
- New PROVENGE® (sipuleucel-T) Data to Be Presented at 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers SymposiumFebruary 13, 2013--Dendreon Corporation (NASDAQ: DNDN) today announced that results from several ongoing or completed studies investigating the utility of PROVENGE® (sipuleucel-T) ... read more
Wednesday, January 30, 2013
- Dendreon to Host Conference Call on February 25 to Announce Fourth Quarter and Full Year 2012 Financial Results and Webcast Presentations at Upcoming ConferencesDendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, February 25, 2012, at 9:00 a.m. ET to review fourth quarter and full year 2012 financial results. ... read more
Monday, January 7, 2013
- Dendreon Announces Preliminary Fourth Quarter 2012 RevenuesDendreon Corporation (NASDAQ: DNDN) today announced preliminary revenues for the fourth quarter ended December 31, 2012. Net product revenue for the quarter is expected to be approximately $85.5 ... read more
Thursday, December 20, 2012
- Dendreon Sells New Jersey Immunotherapy Manufacturing FacilityDendreon Corporation (NASDAQ: DNDN) today announced the sale of its immunotherapy manufacturing facility (IMF) based in Morris Plains, New Jersey, to Novartis Pharmaceuticals Corporation for $43 million in ... read more
Tuesday, November 27, 2012
- Dendreon Announces Webcast Presentations at Upcoming ConferencesNovember 27, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that management will present at the following conferences: ... read more